Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQ05105 + TQB3617 in intermediate- and high-risk myelofibrosis
NCT06122831Phase 2Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQB3617 in myelofibrosis (MF), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Dec 2023; status: recruiting.
02
Drugs
TQB3617
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT06122831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06122831.